Body surface area as a determinant of pharmacokinetics and drug dosing

Investigational New Drugs

Volumn 19, Issue 2, 2001, Pages 171-177

  Sawyer, Michael ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Body surface area; Dosage; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; DACTINOMYCIN; EPIRUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; THIOTEPA;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; HEART OUTPUT; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTHROPOMETRY; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; CARBOPLATIN; CARDIAC OUTPUT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; KIDNEY; LIVER; MEDICAL ONCOLOGY; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0035015115     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010639201787     Document Type: Article

References (39)

1. The use of body surface area as a criterion of drug dosage in cancer chemotherapy
2. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man
3. A Formula to estimate the approximate surface area if height and weight be known
4. Human surface area: Comparison of the Du Bois formula with direct photometric measurement
5. Estimation of human body surface area from height and weight
6. Simplification of drug dosage calculation by application of the surface area principle
7. Body size and metabolism
8. Liver volume as a determinant of drug clearance in children and adolescents
9. Relationships among liver and kidney volumes, lean body mass and drug clearance
10. Disposition of antipyrine and phenytoin correlated with age and liver volume in man
11. Antipyrine disposition and liver size in the elderly
12. Liver size in evaluating drug metabolizing capacity in man
13. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man
14. Classics in clinical science: The concept of renal clearance
15. Studies of kidney function in children
16. The influence of body size on urea output
17. The dependence of the normal kidney function on the size of the body
18. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients
19. Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in ninety normal humans
20. Estimated lean body mass as an index for normalization of body fluid volumes in humans
21. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
22. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight
23. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability
24. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin
25. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer
26. Is dose normalization to weight or body surface area useful in adults?
27. Lean body mass, body surface area and epirubicin kinetics
28. What is the effect of adjusting epirubicin doses for body surface area?
29. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
30. New perspectives on an old friend: Optimizing carboplatin for the treatment of solid tumors
31. Phase I studies with carboplatin at the Royal Marsden Hospital
32. Prospective validation of a simple formula for determining carboplatin dosage
33. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum
34. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
35. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients
36. Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity
37. Population pharmacokinetics of total and unbound etoposide
38. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative